Karla Montalbán-Hernández
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Karla Montalbán-Hernández has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Pascual-Iglesias
The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, 28046 Madrid, Spain
1 shared publication - Carlos del Fresno
The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, 28046 Madrid, Spain
1 shared publication - Cristina Barragán
The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, 28046 Madrid, Spain
1 shared publication - Cristóbal Marcano
The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, 28046 Madrid, Spain
1 shared publication - Eduardo López-Collazo
The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.
1 shared publication - Gloria Cristina Bonel Pérez
The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, 28046 Madrid, Spain
1 shared publication
Latest Publications
- Open Access
Soluble SIGLEC5: A New Prognosis Marker in Colorectal Cancer Patients
Colorectal cancer (CRC) is the second most deadly and third most commonly diagnosed cancer worldwide. There is significant heterogeneity among patients with CRC, which hinders the search for a standard approach for the detection of this disease. Therefore, the identification of robust prognostic markers for patients with CRC represents an urgent clinical need. In search of such biomarkers, a total of 114 patients with colorectal cancer and 67 healthy participants were studied. Soluble SIGLEC5 (sSIGLEC5) levels were higher in plasma from patients with CRC compared with healthy volunteers. Additionally, sSIGLEC5 levels were higher in exitus than in survivors, and the receiver operating characteristic curve analysis revealed sSIGLEC5 to be an exitus predictor (area under the curve 0.853; cut-off > 412.6 ng/mL) in these patients. A Kaplan–Meier analysis showed that patients with high levels of sSIGLEC5 had significantly shorter overall survival (hazard ratio 15.68; 95% CI 4.571–53.81; p ≤ 0.0001) than those with lower sSIGLEC5 levels. Our study suggests that sSIGLEC5 is a soluble prognosis marker and exitus predictor in CRC.
Open AccessSoluble SIGLEC5: A New Prognosis Marker in Colorectal Cancer Patients
Colorectal cancer (CRC) is the second most deadly and third most commonly diagnosed cancer worldwide. There is significant heterogeneity among patients with CRC, which hinders the search for a standard approach for the detection of this disease. Therefore, the identification of robust prognostic markers for patients with CRC represents an urgent clinical need. In search of such biomarkers, a total of 114 patients with colorectal cancer and 67 healthy participants were studied. Soluble SIGLEC5 (sSIGLEC5) levels were higher in plasma from patients with CRC compared with healthy volunteers. Additionally, sSIGLEC5 levels were higher in exitus than in survivors, and the receiver operating characteristic curve analysis revealed sSIGLEC5 to be an exitus predictor (area under the curve 0.853; cut-off > 412.6 ng/mL) in these patients. A Kaplan–Meier analysis showed that patients with high levels of sSIGLEC5 had significantly shorter overall survival (hazard ratio 15.68; 95% CI 4.571–53.81; p ≤ 0.0001) than those with lower sSIGLEC5 levels. Our study suggests that sSIGLEC5 is a soluble prognosis marker and exitus predictor in CRC.